An antidote developed specifically for dabigatran successfully reversed the effects of the anti-clotting medication in healthy volunteers, according to research presented at the American Heart Association's Scientific Sessions 2013.

Researchers developed an antibody fragment (Fab) that specifically binds dabigatran and prevents it from inhibiting clot formation. Fab was given as 1 hour or 5-minute infusions to 145 healthy male volunteers. Immediate, complete and sustained reversal of dabigatran-induced anticoagulation was observed.The antidote is still under development and is not yet approved for clinical use, researchers said.
Source-Eurekalert